Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pro-B3
- Development stage
- Unknown
- Lead developer
- Lallemand Health Solutions
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
Pro-B3 is a multi-strain probiotic formulation designed to restore and maintain the balance of intestinal microbiota. It contains a specific blend of lyophilized bacteria, including *Lactobacillus helveticus* R52, *Bifidobacterium infantis* R33, and *Bifidobacterium bifidum* R71, which are proprietary strains developed by Lallemand Health Solutions. The mechanism of action involves the competitive inhibition of enteric pathogens, the production of organic acids (such as lactic acid) to lower luminal pH, and the enhancement of the intestinal epithelial barrier function. Additionally, Pro-B3 interacts with the gut-associated lymphoid tissue (GALT) to modulate local and systemic immune responses. It is primarily indicated for the management of acute infectious diarrhea, antibiotic-associated diarrhea, and symptoms of irritable bowel syndrome (IBS).
- Brand names
- Pro-B3Pro-B-3Pro-B 3
- Other names
- Pro-B3 ProbioticPro-B-3 ProbioticPro-B 3 ProbioticLactobacillus helveticus R52 + Bifidobacterium infantis R33 + Bifidobacterium bifidum R71
Beyond the preview
Go deeper on Pro-B3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pro-B3.